KAJIAN PENGGUNAAN DAN EFEK SAMPING RISPERIDONE DI RUMAH SAKIT JIWA GRHASIA YOGYAKARTA
Abstract
Risperidone is an atypical antipsychotic indicated for acute and chronic schizophrenia and mania. A study found that the use of risperidone as a therapy for acute schizophrenia was 25.32%. Side effects of risperidone include insomnia, anxiety, headache, and extrapyramidal symptoms. With the high use of risperidone and the many possible side effects, it is necessary to study the drug. This study aims to describe the use and side effects of risperidone at the Ghrasia Mental Hospital Yogyakarta. This research is non-experimental research using a descriptive design. Data were collected retrospectively from medical records of a patient who received risperidone prescriptions at the Grhasia Mental Hospital Yogyakarta January-December 2019. Sampling used the purposive sampling technique, and 360 samples were obtained. The incidence of side effects was analyzed using the Naranjo algorithm. The use of risperidone at the Ghrasia Mental Hospital Yogyakarta showed that patients improved 25.83%, patients improved but had to control 71.17%. The incidence of side effects was 15% of the total 360 patients taking risperidone. The most common
side effects were tremor (4.72%), insomnia 2.50%, nausea 1.67%, and vomiting 1.39%. Side effects were treated with 65% additional therapy, 22% no additional therapy, and 13% drug discontinuation. Conclusion: The use of risperidone at Ghrasia Hospital Yogyakarta shows good effectiveness with a 15% incidence of side effects that are handled properly
References
Badan Pengawas Obat dan Makanan, P.I.O.N., 2020. Risperidon | PIO Nas [WWW Document]. URL http://pionas.pom.go.id/cari/konten/risperidone (accessed 11.4.20).
Ceylan, M.F., Erdogan, B., Tural Hesapcioglu, S., Cop, E., 2017. Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents. Clin. Drug Investig. 37, 947–956. https://doi.org/10.1007/s40261-017-0555-7
Chopko, T.C., Lindsley, C.W., 2018. Classics in Chemical Neuroscience: Risperidone. ACS Chem. Neurosci. 9, 1520–1529. https://doi.org/10.1021/acschemneuro.8b00159
DiPiro, J.T. (Ed.), 2020. Pharmacotherapy: a pathophysiologic approach, 11th ed. McGraw-Hill Medical, New York.
Dziwota, E., Stepulak, M.Z., Włoszczak-Szubzda, A., Olajossy, M., 2018. Social functioning and the quality of life of patients diagnosed with schizophrenia. Ann. Agric. Environ. Med. AAEM 25, 50–55. https://doi.org/10.5604/12321966.1233566
Elvira, S.D., Hadisukanto, G., 2014. Buku ajar psikiatri / Sylvia D. Elvira, editor, Gitayanti Hadisukanto, editor. BP FKUI.
Filts, Y., Litman, R.E., Martínez, J., Anta, L., Naber, D., Correll, C.U., 2022. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. Schizophr. Res. 239, 83–91. https://doi.org/10.1016/j.schres.2021.11.030
Fujian Song, 1997. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J. Psychopharmacol. (Oxf.) 11, 65–71. https://doi.org/10.1177/026988119701100116
Hariyanto, I., Putri, R.A., Untari, E.K., 2016. Different Type of Antipsychotic Therapies on Length of Stay of Acute Schizophrenia Patients in Sungai Bangkong Regional Mental Hospital Pontianak. Indones. J. Clin. Pharm. 5, 115–122. https://doi.org/10.15416/ijcp.2016.5.2.115
Hasan, A., Falkai, P., Lehmann, I., Gaebel, W., 2020. Schizophrenia. Dtsch. Arzteblatt Int. 117, 412–419. https://doi.org/10.3238/arztebl.2020.0412
Indriani, A., Ardiningrum, W., Febrianti, Y., 2020. Studi Penggunaan Kombinasi Antipsikotik pada Pasien Skizofrenia di Rumah Sakit Yogyakarta. Maj. Farmasetika 4. https://doi.org/10.24198/mfarmasetika.v4i0.25882
Lacy, C.F., Armstrong, L.L., Goldman, M.P., Lance, L.L., 2018. Drug Information Handbook 27th edition (9781591953708) - Textbooks.com, 27th edition. Lexicomp.
Maylani, R.Y., Fadraersada, J., Ramadhan, A.M., 2018. Studi Pemberian Antipsikotik terhadap Beberapa Jenis Skizofrenia Di RSJD Atma Husada Mahakam Samarinda. Proceeding Mulawarman Pharm. Conf. 8, 267–275. https://doi.org/10.25026/mpc.v8i1.333
Padmasari, S., 2019. Evaluasi Rasionalitas Penggunaan Obat Antipsikotik Pada Pasien Skizofrenia Di Instalasi Rawat Inap Rumah Sakit Jiwa Grhasia Yogyakarta Tahun 2017. Acta Holistica Pharm. 1, 25–32.
Radiah, N., 2020. Analisis Pemantauan Efek Samping Penggunaan Obat Anti Psikosis Pada Pasien Skizofrenia di Ruang Rawat Inap Rumah Sakit Jiwa Mutiara Sukma Provinsi NTB. J. Ilmu Kesehat. Dan Farm. UNWMataram 8, 3.
Republik Indonesia, K.K., 2022. Profil-Kesehatan-2021.pdf.
Rhee, T.G., Rosenheck, R.A., 2019. Does improvement in symptoms and quality of life in chronic schizophrenia reduce family caregiver burden? Psychiatry Res. 271, 402–404. https://doi.org/10.1016/j.psychres.2018.12.005
Rissa, M.M., Darmawan, E., Siwinarni, A., 2020. Profil Penggunaan Obat Kombinasi Risperidone-Clozapine dan Risperidone dengan Antipsikotik Lain pada Pasien Gangguan Mental Psikotik di Rumah Sakit Jiwa Grhasia Yogyakarta. J. Surya Med. 5, 131–138. https://doi.org/10.33084/jsm.v5i2.1320
Robinson, D.G., Gallego, J.A., John, M., Petrides, G., Hassoun, Y., Zhang, J.-P., Lopez, L., Braga, R.J., Sevy, S.M., Addington, J., Kellner, C.H., Tohen, M., Naraine, M., Bennett, N., Greenberg, J., Lencz, T., Correll, C.U., Kane, J.M., Malhotra, A.K., 2015. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophr. Bull. 41, 1227–1236. https://doi.org/10.1093/schbul/sbv125
